A Next Generation Sequencing Approach to Influenza Vaccine Development

NGS approach to strain identification and genomic characterization of influenza

Influenza typing/identification is enabled by serological tests as well as genotyping of discrete regions of the viral genome. In contrast to Sanger sequencing, Next Generation Sequencing (NGS) provides a streamlined, high-throughput approach to strain identification and broader genomic characterization of influenza, including viral evolution in the wild or in response to vaccine or antiviral challenges.

We can use that sequence information to inform future development of vaccines and therapeutics. NGS presents new possibilities for influenza vaccine development. In this white paper, you will explore the challenges of developing influenza vaccines and new approaches that may eventually lead to a more universal solution.

Complete the form below to access this white paper